Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept biosimilar + methotrexate
- Development stage
- Unknown
- Lead developer
- Samsung Bioepis
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
A combination therapy consisting of an etanercept biosimilar and methotrexate. Etanercept biosimilars are tumor necrosis factor (TNF) blockers that reduce levels of active TNF in the body, while methotrexate is a disease-modifying antirheumatic drug (DMARD). This combination has shown greater efficacy than methotrexate monotherapy in treating rheumatoid arthritis and other inflammatory conditions.
- Other names
- TNF-alpha receptor Fc fusion protein + methotrexaterhTNFR-Fc + MTXTNF receptor II Fc fusion protein + methotrexate
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on etanercept biosimilar + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept biosimilar + methotrexate.